Q BioMed Inc's (OTCQB:QBIO) Kristin Keller tells Proactive the New York-based biotech has launched a Named Patient Program (NPP) to bring its non-opioid bone metastasis pain drug Strontium89 to patients around the world starting in September. Keller says the NPP allows Strontium89 to be provided to patients internationally without needing additional regulatory approval in their countries.
Q BioMed to bring metastatic bone pain drug to patients around the world with launch of new program
Quick facts: Q BioMed Inc.
Price: 1.07 USD
Market Cap: $25.05 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE